A Phase 3 clinical trial involving cagrilintide, as part of the combination CagriSema, entered recruiting status as of July 30, 2026. The study, registered as NCT07564414, is titled "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight."
According to the registration, the trial is designed to examine two different doses of CagriSema alongside one dose of semaglutide in people living with obesity, with or without type 2 diabetes. The trial is currently listed as recruiting participants and is classified as a Phase 3 study.
Cagrilintide remains an unapproved compound under research and has not received regulatory approval for any indication. No outcome data, efficacy results, or safety findings have been posted for this trial at this stage. The current update reflects only the trial's status as recruiting and its stated purpose as described in the registration.
Further details on trial design, eligibility, and any future results will be available through the official registration listing as the study progresses. Readers can consult the compound overview for additional context on cagrilintide.